This year’s developments in the Biosimilars industry demonstrate that the time for hesitation has passed and that innovators must have a plan for entering the U.S. Biosimilars market. Join partner John Callahan at this year’s U.S. Biosimilar’s conference in Munich. This flagship conference is a must see for EU companies who plan on doing business in the U.S.
John Callahan will lend his expertise in one of the most watched areas of patent procedures – Post Grant Review – which go directly to the heart of a patent validity challenge. The conference will be held at the Sheraton Munich on April 21, 2015. For more information on the Biosimilars conference, please click here